Pictured: ESK1 Monoclonal Antibody
In the Lab
By Julie Grisham, MS, Science Writer/Editor  |  Wednesday, March 13, 2013

Scientists from Memorial Sloan Kettering have collaborated on the discovery of a unique monoclonal antibody, called ESK1, that appears to be effective at targeting and destroying several types of cancer cells.

Pictured: James Fagin
In the Clinic
By Media Staff  |  Thursday, February 14, 2013

Researchers have found that the investigational drug selumetinib shuts down the signaling of genetic mutations that prevent some patients’ thyroid cancer tumors from absorbing radioiodine, the most effective treatment for the disease.

Pictured: Neurons
In the Lab
By Jim Stallard, MA, Writer/Editor  |  Monday, February 11, 2013

Researchers have clarified the process by which developing nerve cells are directed to specialize into distinct parts.

Pictured: BCG
In the Lab
By Jim Stallard, MA, Writer/Editor  |  Friday, February 1, 2013

Researchers have shed light on how an important treatment for early-stage bladder cancer enters cancer cells to eradicate them.

Pictured: Kenneth Yu
In the Clinic
By Media Staff  |  Tuesday, January 29, 2013

New research suggests that analyzing genetic changes found in the bloodstream may help doctors predict which chemotherapy regimens will work for some patients.

Pictured: Mark Bilsky
In the O.R.
By Jim Stallard, MA, Writer/Editor  |  Friday, January 25, 2013

Our doctors have shown that tumors compressing the spinal cord can be controlled using less-invasive surgery combined with a precise, intense form of radiation therapy.

Pictured: Prasad Adusumilli
In the Lab
By Julie Grisham, MS, Science Writer/Editor  |  Thursday, January 3, 2013

A team from Memorial Sloan Kettering has found that the makeup of immune cells in a lung tumor and in tissue surrounding a tumor can predict whether the cancer will recur after surgery.

Pictured: Marcel R. M. van den Brink
In the Clinic
By Jim Stallard, MA, Writer/Editor  |  Friday, December 21, 2012

Memorial Sloan Kettering researchers have shown for the first time that administering a growth factor called interleukin-7 can help patients regenerate T cells more quickly after stem cell transplantation.

Pictured: X-ray Image
In the Lab
By Eva Kiesler, PhD, Science Writer/Editor  |  Wednesday, December 19, 2012

Scientists have identified genes and biological mechanisms that one day could be targeted with drugs to stop kidney cancer from spreading to the bone, brain, or other organs.

Pictured: Michel Sadelain
In the Lab
By Julie Grisham, MS, Science Writer/Editor  |  Tuesday, December 18, 2012

Memorial Sloan Kettering researchers have reported a new method that could allow the development of more-specific, cell-based therapies for cancer.

Pictured: Ming Li
Q&A
By Eva Kiesler, PhD, Science Writer/Editor  |  Friday, December 14, 2012

Recent findings by Memorial Sloan Kettering immunologists might one day pave the way for new strategies to control a range of diseases, including autoimmune disorders and cancer.

Pictured: Paul Chapman
Finding
By Memorial Sloan Kettering  |  Friday, December 7, 2012

Memorial Sloan Kettering experts add to their knowledge of vemurafenib, a drug recently approved by the FDA to treat some patients with metastatic melanoma.

Pictured: Michael Zelefsky
In the Clinic
By Andrea Peirce, BA and Media Staff
Friday, November 30, 2012

Study signals hope for maintaining sexual function in men undergoing radiation treatment for prostate cancer.

Pictured: PET Scan
In the Lab
By Eva Kiesler, PhD, Science Writer/Editor  |  Thursday, November 15, 2012

Researchers at Memorial Sloan Kettering are developing a new strategy for PET imaging of tumors that could result in new tools to detect and monitor prostate cancer.

Pictured: Marc Ladanyi & Snjezana Dogan
In the Clinic
By Jim Stallard, MA, Writer/Editor  |  Friday, November 9, 2012

A genetic analysis of tumors suggests women are more susceptible than men to the most common form of lung cancer.

Center News

Stay Informed

Get the latest information about cancer care and research every month.